Coexistence of TERT C228T mutation and MALAT1 dysregulation in primary glioblastoma: new prognostic and therapeutic targets.

: This study was designed to conduct molecular classification based on , and changes in pediatric and adult primary glioblastoma (GB) and to analyze the potential interaction of LncRNA MALAT1 in the determined homogeneous subgroups. We analyzed the expression profiles of and MALAT1 using the qRT-PCR method and and mutation status using DNA sequencing analysis in 85 primary pediatric and adult GB patients. mutation was observed in 5 (5.88%) and mutation in 65 (76.47%) primary pediatric and adult GB patients. and were detected in 18 (21.18%) and 7 (8.24%) patients. mutation and loss of were associated with short overall survival (p < 0.001, p < 0.001, respectively). Patients carrying especially C228T mutation had worse prognosis (p < 0.001). Six subgroups were obtained from the genetic analysis. Among the subgroups, MALAT1 was highly expressed in group A that had a single mutation as compared to that in groups D and E (p = 0.001 and p < 0.001, respectively); further, high MALAT1 expression was associated with worse prognosis in patients with C228T mutation (p < 0.001). Our findings highlight that the presence of C228T mutation and expression of MALAT1 can be used as primary targets during the follow-up of primary GB patients and in the development of new treatment strategies.